ReviewReviews in endocrine & metabolic disorders2007
HER2 targeted therapy in breast cancer...beyond Herceptin.
Review in Reviews in endocrine & metabolic disorders, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 41 citations in OpenAlex.
- Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX.Iranian journal of basic medical sciences · 2015Article
- Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression.Breast cancer research : BCR · 2013Article
- HER2 Ile655Val Single Nucleotide Polymorphism in Patients with Ovarian Cancer.Iranian Red Crescent medical journal · 2013Article
- Expression of EBV encoded viral RNA 1, 2 and anti-inflammatory cytokine (interleukin-10) in FFPE lymphoma specimens: a preliminary study for diagnostic implication in Pakistan.Diagnostic pathology · 2011Article
- Deciphering the anticancer mechanisms of sunitinib.Cancer biology & therapy · 2010Article
- Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.The Journal of biological chemistry · 2010Article
- Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner.Cancer chemotherapy and pharmacology · 2010Article
- Article
- Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies.Molecular oncology · 2009Article
- Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.Journal of virology · 2008Article
- The knowledge-integrated network biomarkers discovery for major adverse cardiac events.Journal of proteome research · 2008Article
- Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases.Molecular pharmaceuticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HER2, is a member of the ErbB family of receptor tyrosine kinases, that plays a key role in the pathogenesis of breast cancer, and when overexpressed, can correlate with a particularly aggressive clinical phenotype. It is estimated in roughly 18 to 20% of breast cancer patients, there is amplification of the HER2 gene resulting in aberrant overexpression of p185HER2 protein. As such, HER2 represents an attractive therapeutic target. In this review, we explore the clinical evolution of trastuzumab, a humanized monoclonal antibody with high specificity and affinity for the HER2 extracellular domain, and additionally examine more recent efforts targeting the intracellular tyrosine kinase domain of HER2 using small molecule tyrosine kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.